Viatris delivered flat sales and 6% adjusted earnings per share growth in its third quarter and raised full-year guidance for both figures by a low-single-digit percentage. Shares fell 1% in Nov. 5 intraday trading.
Recent additions to the pipeline, which span many attractive therapeutic areas, should support Viatris' long-term growth potential and margin expansion.
Base business erosion will persist in developed markets and act as a headwind that Viatris must try to offset with new product launches.
Metric | VTRS | TEVA | SDZ |
|---|---|---|---|
Price/Earnings (Normalized) | 7.90 | 15.68 | 49.27 |
Price/Book Value | 1.83 | 6.23 | 4.99 |
Price/Sales | 1.56 | 2.91 | 3.96 |
Price/Cash Flow | 8.57 | 16.39 | 40.75 |
Metric | VTRS | TEVA | SDZ |
|---|---|---|---|
Quick Ratio | 0.82 | 0.51 | 0.50 |
Current Ratio | 1.55 | 0.95 | 1.05 |
Interest Coverage | −0.11 | 1.42 | 4.66 |
Metric | VTRS | TEVA | SDZ |
|---|---|---|---|
Return on Assets (Normalized) | 8.21% | 6.94% | 7.69% |
Return on Equity (Normalized) | 20.56% | 35.60% | 18.79% |
Return on Invested Capital (Normalized) | 11.60% | 13.90% | 12.29% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|#wV>#pYQ | LOCK|YT<L& | $73B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|MQS>?bl$ | LOCK|?LB< | $48B | |||
| Haleon PLC ADR HLN | LOCK|g?gyY^ | LOCK|N^# | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|m@%J&ytm | LOCK|@Vj | $32B | |||
| Elanco Animal Health Inc ELAN | LOCK|>#c | LOCK|Bdl | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|!k^CKh | LOCK|ZY@ | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|k$Lxz<> | LOCK|>k | $6B | |||
| Perrigo Co PLC PRGO | LOCK|#L^W^^^ | LOCK|?r@ | $2B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|Y?Zct<D | LOCK|<%<Y$ | $2B |
United States